Product Description
Thiabendazole is a broad spectrum anthelmintic agent used predominantly in treatment of intestinal pinworm and strongyloides infection, which recently has been replaced by better tolerated agents. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Thiabendazole)
Mechanisms of Action: Fumarate Reductase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Brazil | Canada | India | Ireland | Italy | Malaysia | New Zealand | Portugal | Taiwan | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|